|
|
|
|
 |
MOUNTAIN VIEW--- REGiMMUNE Raises $8,000,000 in Series B Financing |
| 5/10/2008 @ 8:07 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today that it has closed its Series B financing for a total of $8 million U.S. Proceeds from the financing will be used to advance the company's lead program, RGI-2001, to human clinical trials for graft versus host disease (GvHD). Preclinical development for GvHD associated with bone marrow transplantation has been completed and an Investigation New Drug application is expected to be filed in late 2008.
"This financing underscores our ability to make significant progress towards the clinic and eventual product commercialization," commented Haru Morita, President and Chief Executive Officer of REGiMMUNE. "To thrive as REGiMMUNE has, in a very difficult business environment for many biotech companies in Japan, is a particularly great achievement."
New and existing investors include NIF SMBC Ventures Co., Ltd.; CSK Venture Capital Co., Ltd.; Japan Asia Investment Co., Ltd. and Yasuda Enterprise Development Co., Ltd.
The company's proprietary technology platform, MultiVax, induces antigen-specific immune tolerance via induction of Tregs, a T-cell subset that plays a central role in controlling immune responses to self-antigens and pathogens when administered at the time of exposure to disease-causing antigens. Because of its specificity in targeting immune suppression, MultiVax is anticipated to exhibit higher efficacies with more favorable safety profiles over current immunomodulatory drugs.
RGI-2001 for GvHD
REGiMMUNE plans to start development of its MultiVax product RGI-2001 to treat GvHD following allogeneic stem cell transplantation (SCT) primarily for bone marrow transplants. A major clinical challenge associated with allogeneic SCT is to maintain a fine balance of the immune system to prevent GvHD, serious infection, and/or recurrence of malignancy. This balance is critical because intensive immune suppression will result in infection and recurrence of malignancy while insufficient immune suppression may cause GvHD.
Serious GvHD occurs in up to 40% of HLA-matched allogeneic SCT cases, and 100% in haploidentical, related allogeneic SCT. Current treatment is prophylactic use of immunosuppressants such as cyclosporine A. High-dose steroids are administered once GvHD occurs but the condition often progresses to steroid refractory status and there is no proven second-line therapy for steroid refractory GvHD. Prevention and treatment of GvHD thus represent high unmet medical needs addressing serious, life-threatening conditions. If alloantigen specific, selective immune suppression can be induced with RGI-2001, it would be possible to suppress GvHD while maintaining protective immune responses to infection and recurrence of malignancy.
About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. In addition to its potential for GvHD, MultiVax is a therapeutic candidate for autoimmune diseases such as Multiple Sclerosis (MS) and Systemic Lupus, in which down-regulation of and/or dysfunction of regulatory T-cells lead to serious up-regulation of immunity against the auto-antigen. reVax is the company's second proprietary technology platform, which works by modulating the immune system by enhancing antigen-specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis and MS, where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. For more information, please visit www.regimmune.com. |
| FreshMoney - California Mergers/Acquisitions/Funding |
|
|
| |
| Thursday, July 24, 2008 |
 |
|
ALISO VIEJO--- Microsoft to Acquire DATAllegro Posted 3:36 PM PST
|
| |
| Wednesday, July 23, 2008 |
|
|
SAN DIEGO--- Verimatrix Series C Investment Led by Goldman Sachs; Accelerates Penetration of New Pay-TV Markets Posted 6:55 AM PST
|
| |
| Tuesday, July 22, 2008 |
|
|
SAN DIEGO--- Certona Closes $7 Million Series A Financing; ABS Ventures leads round with participation from previous investor Express Ventures Posted 7:33 AM PST
|
| |
| Monday, July 21, 2008 |
|
|
SAN JOSE--- Brocade Announces Definitive Agreement to Acquire Foundry Networks Posted 4:37 PM PST
SUNNYVALE--- Rohati Systems Secures $12 Million in Series B Funding to Advance Network-Based Entitlement Control Posted 8:57 AM PST
SAN DIEGO--- Optimer Pharmaceuticals to Raise $12.2 Million in Registered Direct Offering Posted 8:30 AM PST
|
| |
| Friday, July 18, 2008 |
|
|
SAN FRANCISCO--- ON24 Closes Over $8 Million in Financing Posted 3:59 PM PST
SAN FRANCISCO-- SOMA Networks Secures Additional $51 Million in Financing Posted 6:50 AM PST
LOS ANGELES--- ViewPartner Corporation Buys PodTech; Plans to Invest and Take Podcasting to the Next Level Posted 6:48 AM PST
|
| |
| Thursday, July 17, 2008 |
|
|
EL SEGUNDO--- Isuppli Acquires Leading Automotive Electronics Analysis Firm Telematics Research Group Posted 7:25 AM PST
MOUNTAIN VIEW--- Become.com Raises $8 Million Investment From European Founder’s Fund Posted 7:20 AM PST
|
| |
| Tuesday, July 15, 2008 |
|
|
CAMPBELL--- YouSendIt Inc. Secures $14 Million in Series C Financing Posted 7:23 AM PST
ALISO VIEJO--- Snipitron Acquires OnlyWire.Com Posted 7:23 AM PST
|
| |
| Monday, July 14, 2008 |
|
|
NEWPORT BEACH--- Stockholders Approve Acquisition of TriZetto by Apax Partners Posted 3:02 PM PST
SAN FRANCISCO--- Engine Yard Closes $15 Million in Series B Financing Posted 6:15 AM PST
SAN JOSE--- A10 Networks Secures $23 Million in Series C Funding Posted 6:11 AM PST
BURBANK--- Point.360 Acquires the Assets of DNS Digital Post Posted 6:10 AM PST
|
| |
| Friday, July 11, 2008 |
|
|
SANTA CLARA--- Impinj Acquires Intel's UHF RFID Reader Chip Operation Posted 8:44 AM PST
SAN JOSE--- Cisco Announces Investment in Venture Capital Fund to Focus on Russia and CIS Posted 8:32 AM PST
LOS ANGELES--- Signalife Board Approves Merger Posted 8:26 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
